期刊文献+

肾衰患者连续性血液滤过时万古霉素的药效学及药动学研究 被引量:1

Investigation of the pharmacodynamics and pharmacokinetics of vancomycin during continuous veno-venous hemofiltration therapy in a patient with renal failure
暂未订购
导出
摘要 目的 了解肾衰患者进行连续性静静脉血液滤过 (continuousveno venoushemofiltration ,简称CVVH)过程中万古霉素的药效学及药动学特征 ,为万古霉素的合理使用提供依据。方法 采用荧光偏振免疫分析仪测定使用万古霉素第 3天、第 16天时 ,给药后不同时间血中药物浓度 ,以PKBP N1药动学软件包对所测得的药物浓度 时间数据进行拟合 ,计算药动学参数。并监测用药过程中万古霉素血药浓度谷值及药效学指标。结果 进行CVVH时 ,万古霉素的体内药动学过程呈开放型二房室模型。其药动学参数为 :使用万古霉素第 3天时 ,t1/ 2α=0 .41h ,t1/ 2 β=5 .75h ,Vc =2 1.92L ,cmax=2 2 .81μg·mL-1,cmin=5 .82 μg·mL-1,CL =3.49L·h-1,VSS=2 8.32L。第 16天时 ,t1/ 2α=0 .6 1h ,t1/ 2 β=33.2 3h ,Vc=12 .92L ,cmax=38.70 μg·mL-1,cmin=16 .5 0 μg·mL-1,CL =0 .376L·h-1,Vss=17.6 9L。维持万古霉素的血药浓度谷值在 5~ 10 μg·mL-1有效范围的情况下 ,其用药间隔由用药初期的q8h逐渐延长为用药 17d后的 q48h。药效学指标提示 ,万古霉素从患者体内清除其敏感菌金葡球菌的时间为 38d。结论 进行CVVH治疗时 ,体内万古霉素的药动学过程是可变的。因此 ,必须加强对万古霉素血药浓度的监测 ,及时调整用药方案 。 OBJECTIVE: To investigate the pharmacodynamic and pharmacokinetic properties of vancomycin during continuous veno-venous hemofiltration (CVVH) therapy in a patient with renal failure. METHODS: A patient with kidney failure received 0.5 g vancomycin infusion during CVVH therapy. On 3rd day and 16th day during the therapy, blood samples were collected after the dosing. The serum concentrations of vancomycin were measured by TDx. The pharmacokinetic parameters were calculated using PKBPN1 software. The pharmacodynamic targets of vancomycin were observed. RESULTS: The pharmacokinetics of vancomycin during CVVH was fitted well with open two-compartment model. On the 3rd day of CVVH therapy, the pharmacokinetic parameters were: t1/2α0.41 h, t1/2β5.75 h, Vc 21.92 L, cmax 22.81 μg&middotmL-1, cmin 5.82 μg&middotmL-1, CL 3.49 L and Vss 28.32 L, respectively. On the 16th day, the PK parameters were: t1/2α 0.61 h, t1/2β 33.23 h, Vc 12.92 L, cmax 38.70 μg&middotmL-1,cmin 16.50 μg&middotmL-1, CL 0.367 L and Vss 17.69 L, respectively. The pharmacodynamic targets of vancomycin were body temperature, white blood count and bacteria in phlegm. CONCLUSION: It demonstrated that the pharmacokinetic properties of vancomycin changed with time during CVVH treatment. Therefore, the monitoring of blood drug concentration during the therapy was necessary and the dosage regiment should be adjusted accordingly.
出处 《中国药学杂志》 EI CAS CSCD 北大核心 2001年第11期753-755,共3页 Chinese Pharmaceutical Journal
关键词 连续性血液过滤 万古霉素 药效学 药动学 肾功能衰竭 CVVH Blood Drug dosage Drug therapy Patient treatment Pharmacokinetics
  • 相关文献

参考文献5

  • 1何长明 张训.肾脏替代治疗学[M].上海:上海科学技术文献出版社,1999.171.
  • 2王贤才(译) American medical association.临床药物大典[M].青岛:青岛人民出版社,1992.1221-1223.
  • 3何长明,肾脏替代治疗学,1999年,171页
  • 4王贤才(译),临床药物大典,1992年,1221页
  • 5吴莱文,治疗药物监测,1989年,410页

共引文献11

同被引文献13

  • 1Rybak M, Lomaestro B, Rotschafer JC, et al. Thera- peutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health- System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Phar- macists[J]. Am J Health Syst Pharm, 2009, 66(1): 82-98.
  • 2Lo YL, van Hasseh JG, Heng SC, et al. Population pharmaeokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determi- nation [J]. Antimicrob Agents Chemother, 2010, 54(6): 2626-32.
  • 3Staatz CE, Byrne C, Thomson AH. Population pharma- eokinetie modelling of gentamicin and vancomycin in patients with unstable renal funetion following cardiotho- racie surgery[J]. Br J Clin Pharmacol, 2006, 61(2): 164-76.
  • 4Buelga DS, del Mar Fernandez de Gatta M, Henera EV, et al. Population pharmacokinetic analysis of van- comycin in patients with hematological malignancies[J]. Antimicrob Agents Chemother, 2005, 49(12): 4934-41.
  • 5Wrishko RE, Levine M, Khoo D, et al. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients[J]. Ther Drug Moult, 2000, 22(5): 522-31.
  • 6Sanchez JL, Dominguez AR, Lane JR, et al. Popula- tion pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches[J]. Int J Clin Pharmacol Ther, 2010, 48(8): 525-33.
  • 7Zhang J, Zhang Y, Shi Y, et al. Population pharma- cokinetic and pharmacodynamic modeling of norvan- comycin[J]. Eur J Clin Microbiol Infect Dis, 2008, 27 (4): 275-84.
  • 8Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal mem- brane oxygenation [J]. Br J Clin Pharmacol, 2005, 60 (3): 265-75.
  • 9Ohnishi A, Yano Y, Ishibashi T, et aL Evaluation of Bayesian predictability of vancomycin concentration using population pharmacokinetic parameters in pediatric pa- tients[J]. Drug Metab Pharmaeokinet, 2005, 20(6): 415-22.
  • 10陈小玲,焦晓多.万古霉素在MRSA老年下呼吸道感染患者体内的药代动力学研究[J].现代医院,2009,9(8):9-11. 被引量:5

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部